Comment on

• Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway.

  Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Brinkman K, et al. AIDS. 1998 Oct 1;12(14):1735-44. doi: 10.1097/00002030-199814000-00004. AIDS. 1998. PMID: 9792373 Review. No abstract available.
• A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

  Carr A, Miller J, Law M, Cooper DA. Carr A, et al. AIDS. 2000 Feb 18;14(3):F25-32. doi: 10.1097/00002030-200002180-00001. AIDS. 2000. PMID: 10716495 Clinical Trial.
• Liver toxicity caused by nevirapine.

  González de Requena D, Núñez M, Jiménez-Nácher I, Soriano V. González de Requena D, et al. AIDS. 2002 Jan 25;16(2):290-1. doi: 10.1097/00002030-200201250-00020. AIDS. 2002. PMID: 11807315
• Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.

  Macías J, Castellano V, Merchante N, Palacios RB, Mira JA, Sáez C, García-García JA, Lozano F, Gómez-Mateos JM, Pineda JA. Macías J, et al. AIDS. 2004 Mar 26;18(5):767-74. doi: 10.1097/00002030-200403260-00007. AIDS. 2004. PMID: 15075511
• Care of patients with hepatitis C and HIV co-infection.

  Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, Dieterich D, Hatzakis A, Rockstroh J. Soriano V, et al. AIDS. 2004 Jan 2;18(1):1-12. doi: 10.1097/00002030-200401020-00001. AIDS. 2004. PMID: 15090824 Review. No abstract available.
• Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C.

  Braitstein P, Palepu A, Dieterich D, Benhamou Y, Montaner JS. Braitstein P, et al. AIDS. 2004 Nov 19;18(17):2221-34. doi: 10.1097/00002030-200411190-00002. AIDS. 2004. PMID: 15577534 Review.
• Survival in patients with HIV infection and viral hepatitis B or C: a cohort study.

  Bonacini M, Louie S, Bzowej N, Wohl AR. Bonacini M, et al. AIDS. 2004 Oct 21;18(15):2039-45. doi: 10.1097/00002030-200410210-00008. AIDS. 2004. PMID: 15577625
• How effective is HAART in HCV and HIV coinfection?

  Núñez M, Soriano V. Núñez M, et al. AIDS. 2004 Oct 21;18(15):2081-4. doi: 10.1097/00002030-200410210-00013. AIDS. 2004. PMID: 15577630 No abstract available.
• Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients.

  Mariné-Barjoan E, Saint-Paul MC, Pradier C, Chaillou S, Anty R, Michiels JF, Sattonnet C, Ouzan D, Dellamonica P, Tran A; Registre des Ponctions-Biopsies Hépatiques. Mariné-Barjoan E, et al. AIDS. 2004 Nov 5;18(16):2163-70. doi: 10.1097/00002030-200411050-00008. AIDS. 2004. PMID: 15577649
• Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus.

  Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Sulkowski MS, et al. AIDS. 2005 Mar 24;19(6):585-92. doi: 10.1097/01.aids.0000163935.99401.25. AIDS. 2005. PMID: 15802977